LIRAGLUTIDE

Course overview

LIRAGLUTIDE IS A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA) USED TO TREAT TYPE 2 DIABETES (T2D) AND OBESITY. THIS DRUG BELONGS TO THE INCRETIN MIMETIC CLASS OF ANTIDIABETIC AGENTS AND ACTS ON PANCREATIC Β-CELLS TO STIMULATE THE RELEASE OF ENDOGENOUS INSULIN, HELPING TO CONTROL BLOOD GLUCOSE LEVELS AND SUPPRESS APPETITE. THE FDA APPROVED LIRAGLUTIDE IN 2010 AS A TREATMENT FOR T2D AND IN 2014 FOR WEIGHT LOSS. THIS ACTIVITY REVIEWS LIRAGLUTIDE'S MECHANISM OF ACTION, DOSING, PHARMACODYNAMICS, PHARMACOKINETICS, ADVERSE EVENT PROFILE, OFF-LABEL USES, MONITORING, AND RELEVANT INTERACTIONS. THESE ASPECTS OF LIRAGLUTIDE ARE CRITICAL FOR HEALTHCARE PROFESSIONALS MANAGING PATIENTS WITH T2D AND RELATED CONDITIONS. UNDERSTANDING LIRAGLUTIDE'S PROPER INDICATIONS AND POTENTIAL SIDE EFFECTS SUPPORTS EFFECTIVE COMMUNICATION ACROSS THE INTERPROFESSIONAL HEALTHCARE TEAM.